Pluri (PLUR) said Wednesday that it signed an exclusive collaboration deal with Hemafund, an umbilical cord blood bank, for the distribution and clinical advancement of PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome in Ukraine.
Pluri said it has agreed to produce and supply PLX-R18 and will work with Hemafund to seek funding for the production of an initial 12,000 doses of PLX-R18 to be stored and managed by Hemafund.
The companies plan to sign a separate definitive agreement once the external funding is secured. The collaboration could fetch over $100 million in value for the companies based on the estimated cost and the expected initial stockpile, Pluri said.
The three-year agreement can be extended for three more years, the company said.
Shares of Pluri were up 8.8% in recent Wednesday trading.
Price: 4.69, Change: +0.38, Percent Change: +8.82
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。